MDM2/MDMX inhibitor peptide: WO2008106507

Author： Macchiarulo Antonio   Pellicciari Roberto  

Publisher： Informa Healthcare

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.19, Iss.5, 2009-05, pp. : 721-726

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting MDM2 and MDMX in Retinoblastoma

By  

Current Cancer Drug Targets, Vol. 7, Iss. 7, 2007-11 ,pp. : 689-695

Bentham Science Publishers

Access to resources Recommend Favorite

Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011 – present)

By Zak Krzysztof   Pecak Aleksandra   Rys Barbara   Wladyka Benedykt   Dömling Alexander   Weber Lutz   Holak Tad A   Dubin Grzegorz  

Expert Opinion on Therapeutic Patents, Vol. 23, Iss. 4, 2013-04 ,pp. : 425-448

Informa Healthcare

Access to resources Recommend Favorite

The MDM2 Inhibitor Nutlins as an Innovative Therapeutic Tool for the Treatment of Haematological Malignancies

By  

Current Pharmaceutical Design, Vol. 14, Iss. 21, 2008-07 ,pp. : 2100-2110

Bentham Science Publishers

Access to resources Recommend Favorite

P53 Mdm2 Inhibitors

By  

Current Pharmaceutical Design, Vol. 18, Iss. 30, 2012-10 ,pp. : 4668-4678

Bentham Science Publishers

Access to resources Recommend Favorite

Chemosensitization by Antisense Oligonucleotides Targeting MDM2

By  

Current Cancer Drug Targets, Vol. 5, Iss. 1, 2005-01 ,pp. : 51-56

Bentham Science Publishers

Access to resources Recommend Favorite